Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA. Modi S, et al. Among authors: bagatell r. J Clin Oncol. 2007 Dec 1;25(34):5410-7. doi: 10.1200/JCO.2007.11.7960. J Clin Oncol. 2007. PMID: 18048823 Clinical Trial.
Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.
Pinto N, Naranjo A, Ding X, Zhang FF, Hibbitts E, Kennedy R, Tibbetts R, Wong-Michalak S, Craig DW, Manojlovic Z, Hogarty MD, Kreissman S, Bagatell R, Irwin MS, Park JR, Asgharzadeh S. Pinto N, et al. Among authors: bagatell r. Clin Cancer Res. 2023 Apr 14;29(8):1546-1556. doi: 10.1158/1078-0432.CCR-22-3032. Clin Cancer Res. 2023. PMID: 36749880 Free PMC article.
Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group.
Streby KA, Parisi MT, Shulkin BL, LaBarre B, Bagatell R, Diller L, Grupp SA, Matthay KK, Voss SD, Yu AL, London WB, Park JR, Yanik GA, Naranjo A. Streby KA, et al. Among authors: bagatell r. Pediatr Blood Cancer. 2023 Aug;70(8):e30418. doi: 10.1002/pbc.30418. Epub 2023 May 18. Pediatr Blood Cancer. 2023. PMID: 37199022 Free PMC article. Clinical Trial.
Children's Oncology Group's 2023 blueprint for research: Neuroblastoma.
Bagatell R, DuBois SG, Naranjo A, Belle J, Goldsmith KC, Park JR, Irwin MS; COG Neuroblastoma Committee. Bagatell R, et al. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30572. doi: 10.1002/pbc.30572. Epub 2023 Jul 17. Pediatr Blood Cancer. 2023. PMID: 37458162 Free PMC article.
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.
Erbe AK, Diccianni MB, Mody R, Naranjo A, Zhang FF, Birstler J, Kim K, Feils AS, Hung JT, London WB, Shulkin BL, Mathew V, Parisi MT, Servaes S, Asgharzadeh S, Maris JM, Park J, Yu AL, Sondel PM, Bagatell R. Erbe AK, et al. Among authors: bagatell r. J Immunother Cancer. 2023 Feb;11(2):e006530. doi: 10.1136/jitc-2022-006530. J Immunother Cancer. 2023. PMID: 36822669 Free PMC article.
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
Weigel BJ, Blaney SM, Reid JM, Safgren SL, Bagatell R, Kersey J, Neglia JP, Ivy SP, Ingle AM, Whitesell L, Gilbertson RJ, Krailo M, Ames M, Adamson PC. Weigel BJ, et al. Among authors: bagatell r. Clin Cancer Res. 2007 Mar 15;13(6):1789-93. doi: 10.1158/1078-0432.CCR-06-2270. Clin Cancer Res. 2007. PMID: 17363534 Clinical Trial.
132 results